Insulin resistance and protein catabolism in critically ill patients;Insulinresistenz: Bedeutung in Anästhesie und Intensivmedizin - Insulinresistenz und Proteinkatabolie bei kritisch Kranken

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 46, Issue 4, 2011, Pages 268-274

  Bierbrauer, Jeffrey ^a   Weber Carstens, Steffen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ARTICLE; CRITICALLY ILL PATIENT; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLYCOGENOLYSIS; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTENSIVE CARE UNIT; PROTEIN DEGRADATION;

ANESTHESIA; ATROPHY; BLOOD GLUCOSE; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; INTENSIVE CARE; LIVER; MUSCLE CONTRACTION; MUSCLE, SKELETAL; PROTEINS; STRESS, PHYSIOLOGICAL;

EID: 79954489029     PISSN: 09392661     EISSN: 14391074     Source Type: Journal    
DOI: 10.1055/s-0031-1275784     Document Type: Article

References (63)

1. Freire AX et al. Admission hyperglycemia and other risk factors as predictors of hospital mortality in a medical ICU population. Chest 2005 128 3109-3116 (Pubitemid 41698629)
2. Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Practice & Research. Clinical Endocrinology & Metabolism 2001 15 533-551
3. Siegel JH et al. Physiological and metabolic correlations in human sepsis. Invited commentary. Surgery 1979 86 163-193
4. Frayn KN et al. The relationship of plasma catecholamines to acute metabolic and hormonal responses to injury in man. Circulatory Shock 1985 16 229-240
5. Miyoshi H et al. Hormonal control of substrate cycling in humans. The Journal of Clinical Investigation 1988 81 1545-1555
6. Wolfe RR. Substrate utilization/insulin resistance in sepsis/trauma. Baillière's Clinical Endocrinology and Metabolism 1997 11 645-657 (Pubitemid 28200843)
7. Robinson LE, van Soeren MH. Insulin resistance and hyperglycemia in critical illness: role of insulin in glycemic control. AACN Clinical Issues 2004 15 45-62
8. Mizock BA. Alterations in carbohydrate metabolism during stress: a review of the literature. The American Journal of Medicine 1995 98 75-84
9. Wolfe RR. Carbohydrate metabolism in the critically ill patient. Implications for nutritional support. Critical Care Clinics 1987 3 11-24 (Pubitemid 17231956)
10. Lang C, Dobrescu C, Bagby G. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992 130 43-52
11. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-, Overexpressed in Human Fat Cells from Insulin-resistant Subjects. Journal of Biological Chemistry 2003 278 45777-45784 (Pubitemid 37432722)
12. Agwunobi AO et al. Insulin resistance and substrate utilization in human endotoxemia. The Journal of Clinical Endocrinology and Metabolism 2000 85 3770-3778
13. Sonne MP et al. Effect of 10 days of bedrest on metabolic and vascular insulin action: a study in individuals at risk for type 2 diabetes. Journal of Applied Physiology (Bethesda, Md.: 1985) 2010 830-837
14. Malmberg K et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. Journal of the American College of Cardiology 1995 26 57-65
15. Furnary AP et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. The Annals of Thoracic Surgery discussion 1999 67 360-362
16. van den Berghe G et al. Intensive insulin therapy in the critically ill patients. The New England Journal of Medicine 2001 345 1359-1367
17. van den Berghe G et al. Intensive insulin therapy in the medical ICU. The New England Journal of Medicine 2006 354 449-461 (Pubitemid 43200296)
18. Preiser J et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Medicine 2009 35 1738-1748
19. Brunkhorst FM et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. The New England Journal of Medicine 2008 358 125-139
20. Finfer S et al. Intensive versus conventional glucose control in critically ill patients. The New England Journal of Medicine 2009 360 1283-1297
21. Inzucchi SE, Siegel MD. Glucose Control in the ICU How Tight Is Too Tight? New England Journal of Medicine 2009 360 1346-1349
22. Friedrich JO, Chant C, Adhikari NKJ. Does intensive insulin therapy really reduce mortality in critically ill surgical patients? A reanalysis of meta-analytic data. Critical Care 2010 14 324-324
23. Zaid H et al. Insulin action on glucose transporters through molecular switches, tracks and tethers. The Biochemical Journal 2008 413 201-215
24. Pessin JE, Bell GI. Mammalian facilitative glucose transporter family: structure and molecular regulation. Annual Review of Physiology 1992 54 911-930
25. Saeed M et al. Selective impairment of glucose storage in human sepsis. The British Journal of Surgery 1999 86 813-821 (Pubitemid 29271949)
26. Black PR et al. Mechanisms of insulin resistance following injury. Annals of Surgery 1982 196 420-435 (Pubitemid 12030719)
27. Zauner A et al. Severity of insulin resistance in critically ill medical patients. Metabolism: Clinical and Experimental 2007 56 1-5 (Pubitemid 44855005)
28. McCowen KC et al. Sustained endotoxemia leads to marked down-regulation of early steps in the insulin-signaling cascade. Critical Care Medicine 2001 29 839-846 (Pubitemid 32299726)
29. Xu J et al. Trauma and hemorrhage-induced acute hepatic insulin resistance: dominant role of tumor necrosis factor-alpha. Endocrinology 2008 149 2369-2382 (Pubitemid 351574510)
30. Defalque D et al. GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. The American Journal of Physiology 1999 276 565-572
31. Nakhjavani M et al. Changes in growth hormone and insulin-like growth factor-I levels in the acute stage after open heart surgery and at the time of discharge. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology and German Diabetes Association. 2009 117 413-416
32. Takala J et al. Increased mortality associated with growth hormone treatment in critically ill adults. The New England Journal of Medicine 1999 341 785-792 (Pubitemid 29420473)
33. Latres E et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. The Journal of Biological Chemistry 2005 280 2737-2744 (Pubitemid 40189380)
34. Attard-Montalto SP et al. Changes in protein turnover, IGF-I and IGF binding proteins in children with cancer. Acta Paediatrica 1998 87 54-60 (Pubitemid 28086606)
35. Fan J et al. Differential tissue regulation of insulin-like growth factor-I content and binding proteins after endotoxin. Endocrinology 1994 134 1685-1692 (Pubitemid 24110724)
36. Costelli P et al. IGF-1 is downregulated in experimental cancer cachexia. American Journal of Physiology 2006 291 674-683
37. Argilés JM, López-Soriano FJ. Catabolic proinflammatory cytokines. Current Opinion in Clinical Nutrition and Metabolic Care 1998 1 245-251 (Pubitemid 128539449)
38. Guimarães SM et al. Low insulin-like growth factor-1 and hypocholesterolemia as mortality predictors in acute kidney injury in the intensive care unit. Critical Care Medicine 2008 36 3165-3170
39. Mesotten D et al. Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. The Journal of Clinical Endocrinology and Metabolism 2002 87 5516-5523 (Pubitemid 36034354)
40. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. American Journal of Physiology 2000 278 967-976
41. Nunes AL et al. Tissue-specific regulation of early steps in insulin action in septic rats. Life Sciences 2001 69 2103-2112 (Pubitemid 32907578)
42. Thirone ACP, Huang C, Klip A. Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. TEM 2006 17 72-78
43. Weinstein SP et al. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism: Clinical and Experimental 1998 47 3-6 (Pubitemid 28086224)
44. Green CJ et al. Septic patients in multiple organ failure can oxidize infused glucose, but non-oxidative disposal (storage) is impaired. Clinical Science 1995 89 601-609
45. Wolfe RR et al. Isotopic evaluation of the metabolism of pyruvate and related substrates in normal adult volunteers and severely burned children: effect of dichloroacetate and glucose infusion. Surgery 1991 110 54-67
46. Shangraw RE et al. Pyruvate dehydrogenase inactivity is not responsible for sepsis-induced insulin resistance. Critical Care Medicine 1996 24 566-574 (Pubitemid 26133788)
47. Korshunov SS, Skulachev VP, Starkov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Letters 1997 416 15-18 (Pubitemid 27470791)
48. Hara K et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. The Journal of Biological Chemistry 1998 273 14484-14494 (Pubitemid 28319170)
49. Russell ST et al. Mechanism of induction of muscle protein loss by hyperglycaemia. Experimental Cell Research 2009 315 16-25
50. Bamman MM et al. Mechanical load increases muscle IGF-I and androgen receptor mRNA concentrations in humans. American Journal of Physiology. Endocrinology and Metabolism 2001 280 383-390
51. Strasser EM et al. Neuromuscular electrical stimulation reduces skeletal muscle protein degradation and stimulates insulin-like growth factors in an age- and current-dependent manner: a randomized, controlled clinical trial in major abdominal surgical patients. Annals of Surgery 2009 249 738-743
52. Lund S et al. Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin. Proceedings of the National Academy of Sciences of the United States of America 1995 92 5817-5821
53. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. The New England Journal of Medicine 1996 335 1897-1905 (Pubitemid 26419198)
54. Lecker SH et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2004 18 39-51 (Pubitemid 38076464)
55. Gomes MD et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proceedings of the National Academy of Sciences of the United States of America 2001 98 14440-14445 (Pubitemid 33121410)
56. Bodine SC et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001 294 1704-1708 (Pubitemid 33104839)
57. Cohen S et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. The Journal of Cell Biology 2009 185 1083-1095
58. Li Y et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2005 19 362-370 (Pubitemid 40316524)
59. Adams V et al. Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. Journal of Molecular Biology 2008 384 48-59
60. Sacheck JM et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. American Journal of Physiology 2004 287 591-601
61. Stitt TN et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Molecular Cell 2004 14 395-403 (Pubitemid 38591410)
62. Callahan LA, Supinski GS. Sepsis-induced myopathy. Critical Care Medicine 2009 37 354-367
63. de Jonghe B et al. Intensive care unit-acquired weakness: risk factors and prevention. Critical Care Medicine 2009 37 309-315